Payment overview · 2025
General Payments
$189,463.78
470 reported records · 37 companies
Healthcare provider profile · identity verified
Allan B Perel, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · STATEN ISLAND, NY · NPI 1295700177
Verified facts
What the public records show
CMS Open Payments records show Allan B Perel, M.D. received $189,463.78 in general payments during 2025 across 470 reported records.
TG Therapeutics, Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Botox, Ingrezza, Nourianz, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Tysabri, Ubrelvy, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ongentys by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zeposia by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nourianz by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Rexulti by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ampyra by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39,576.00 | 20.9% | 34 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $25,511.45 | 13.5% | 32 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19,878.25 | 10.5% | 35 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17,821.65 | 9.4% | 82 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15,466.07 | 8.2% | 19 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15,417.45 | 8.1% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $12,530.69 | 6.6% | 30 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11,575.89 | 6.1% | 33 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $10,974.03 | 5.8% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $8,629.58 | 4.5% | 20 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $6,104.83 | 3.2% | 29 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $2,894.06 | 1.5% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $780.55 | 0.4% | 29 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $291.41 | 0.1% | 23 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $268.62 | 0.1% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $190.24 | 0.1% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $158.60 | 0.1% | 10 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $133.83 | 0.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $130.49 | 0.1% | 6 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $129.34 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $128.88 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $120.33 | 0.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $116.57 | 0.1% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$95.55 | 0.1% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $90.21 | 0.1% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $88.35 | 0.1% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $77.19 | 0.0% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $54.74 | 0.0% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $44.10 | 0.0% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $34.74 | 0.0% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $31.74 | 0.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.59 | 0.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.26 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.01 | 0.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.93 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.21 | 0.0% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $16.35 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $122,132.50 | 43 |
| Honoraria | $36,677.50 | 15 |
| Travel and Lodging | $12,589.37 | 50 |
| Food and Beverage | $12,119.59 | 350 |
| Consulting Fee | $3,727.50 | 6 |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,047.50 | 2 |
| Education | $169.82 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $39,576.00 | 34 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $24,324.13 | 16 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19,579.95 | 23 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $15,576.05 | 24 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $15,466.07 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $12,762.62 | 65 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $12,512.06 | 29 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $11,575.89 | 33 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $10,974.03 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $8,612.84 | 18 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $6,023.34 | 28 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5,219.60 | 35 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $3,052.09 | 16 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $398.29 | 6 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $298.30 | 12 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $291.41 | 23 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $262.88 | 14 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $235.51 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $202.35 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $190.24 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $161.04 | 12 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $143.62 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech, Inc. | $133.83 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $130.49 | 6 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $129.34 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $128.88 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $116.57 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $100.12 | 3 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $90.21 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $88.35 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $77.19 | 4 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $44.10 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BOTOX botox |
2025 | Botox | 2024 | 29 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NOURIANZ nourianz |
2025 | Nourianz | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 122 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 81 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 164 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 96 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
164 | 44 |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 856 | 231 |
| Donepezil Hcl | Donepezil Hcl | 580 | 167 |
| Memantine Hcl Er | Memantine Hcl | 490 | 119 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 385 | 93 |
| Pregabalin | Pregabalin | 273 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 254 | 76 |
| Levetiracetam | Levetiracetam | 177 | 41 |
| Baclofen | Baclofen | 170 | 31 |
| Rexulti | Brexpiprazole | 164 | 44 |
| Memantine Hcl | Memantine Hcl | 153 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 54 |
| Trazodone Hcl | Trazodone Hcl | 134 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 39 |
| Dalfampridine Er | Dalfampridine | 127 | 14 |
| Nurtec Odt | Rimegepant Sulfate | 122 | 25 |
| Sertraline Hcl | Sertraline Hcl | 115 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 15 |
| Primidone | Primidone | 109 | 32 |
| Meclizine Hcl | Meclizine Hcl | 97 | 25 |
| Ubrelvy | Ubrogepant | 96 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 86 | 16 |
| Qulipta | Atogepant | 81 | 19 |
| Vumerity | Diroximel Fumarate | 79 | suppressed |
| Ongentys | Opicapone | 71 | 12 |
| Rasagiline Mesylate | Rasagiline Mesylate | 64 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 17 |
| Naproxen | Naproxen | 57 | 28 |
| Topiramate | Topiramate | 56 | 11 |
| Ibuprofen | Ibuprofen | 51 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 13 |
| Oxcarbazepine | Oxcarbazepine | 46 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Prednisone | Prednisone | 44 | 21 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 43 | suppressed |
| Diazepam | Diazepam | 42 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 42 | suppressed |
| Carbamazepine Er | Carbamazepine | 41 | suppressed |
| Modafinil | Modafinil | 41 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 41 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 40 | suppressed |
| Teriflunomide | Teriflunomide | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | 13 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | 13 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Botox | Onabotulinumtoxina | 29 | 14 |
| Dimethyl Fumarate | Dimethyl Fumarate | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Adlarity | Donepezil Hcl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Sumatriptan | Sumatriptan | 21 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ampyra | Dalfampridine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Nourianz | Istradefylline | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Zolmitriptan | Zolmitriptan | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Tecfidera | Dimethyl Fumarate | 15 | suppressed |
| Tysabri | Natalizumab | 15 | suppressed |
| Austedo Xr | Deutetrabenazine | 14 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 14 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Aubagio | Teriflunomide | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $189,463.78 · 470 records | TG Therapeutics, Inc. | ACTHAR, AMVUTTRA, AUSTEDO XR, BOTOX, BREKIYA, BRIUMVI, Bafiertam, Briviact, Dysport, ELYXYB - CELECOXIB, INBRIJA, INGREZZA, JOURNAVX, KISUNLA, LEQEMBI, Mavenclad, NOURIANZ, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Sunosi, Symbravo, TONMYA, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error